Table 3 Summary of treatment-related AEs.

From: Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial

AEa

ITT (n = 141)

A (n = 4)

B (n = 20)

C (n = 46)

D (n = 10)

E (n = 46)

F (n = 6)

G (n = 9)

Any

Grade ≥ 3

Any

Grade ≥ 3

Any

Grade ≥ 3

Any

Grade ≥ 3

Any

Grade ≥ 3

Any

Grade ≥ 3

Any

Grade ≥ 3

Any

Grade ≥ 3

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

n (%)

Nausea

33 (23.4)

0

1 (25.0)

0

2 (10.0)

0

6 (13.0)

0

5 (50.0)

0

18 (39.1)

0

1 (16.7)

0

0

0

Anorexia

21 (14.9)

3 (2.1)

2 (50.0)

0

0

0

2 (4.3)

1 (2.2)

1 (10.0)

0

12 (26.1)

2 (4.3)

4 (66.7)

0

0

0

Vomiting

20 (14.2)

0

1 (25.0)

0

2 (10.0)

0

4 (8.7)

0

3 (30.0)

0

10 (21.7)

0

0

0

0

0

Diarrhea

14 (9.9)

1 (0.7)

3 (75.0)

0

2 (10.0)

1 (5.0)

3 (6.5)

0

0

0

6 (13.0)

0

0

0

0

0

Constipation

3 (2.1)

0

0

0

0

0

1 (2.2)

0

1 (10.0)

0

1 (2.2)

0

0

0

0

0

Dyspnea

6 (4.3)

1 (0.7)

0

0

1 (5.0)

1 (5.0)

1 (2.2)

0

0

0

3 (6.5)

1 (2.2)

1 (16.7)

0

0

0

Cough

9 (6.4)

0

0

0

0

0

2 (4.3)

0

0

0

5 (10.9)

0

2 (33.3)

0

0

0

Fatigue

40 (28.4)

0

1 (25.0)

0

3 (15.0)

0

12 (26.1)

0

1 (10.0)

0

19 (41.3)

0

2 (33.3)

0

2 (22.2)

0

Pyrexia

8 (5.7)

2 (1.4)

0

0

0

0

5 (10.9)

1 (2.2)

0

0

1 (2.2)

0

1 (16.7)

0

1 (11.1)

1 (11.1)

Weight loss

13 (9.2)

0

2 (50.0)

0

0

0

2 (4.3)

0

0

0

8 (17.4)

0

0

0

1 (11.1)

0

Rash

10 (7.1)

1 (0.7)

0

0

0

0

6 (13.0)

1 (2.2)b

0

0

4 (8.7)

0

0

0

0

0

Arthralgia

6 (4.3)

0

0

0

1 (5.0)

0

2 (4.3)

0

1 (10.0)

0

2 (4.3)

0

0

0

0

0

Myalgia

4 (2.8)

0

0

0

0

0

3 (6.5)

0

1 (10.0)

0

0

0

0

0

0

0

Back pain

3 (2.1)

1 (0.7)

0

0

1 (5.0)

0

0

0

0

0

1 (2.2)

0

1 (16.7)

1 (16.7)

0

0

Mucositis

20 (14.2)

0

2 (50.0)

0

2 (10.0)

0

3 (6.5)

0

1 (10.0)

0

6 (13.0)

0

3 (50.0)

0

3 (33.3)

0

PPE

20 (14.2)

3 (2.1)

1 (25.0)

0

0

0

2 (4.3)

0

0

0

17 (37.0)

4 (8.7)

1 (16.7)

0

0

0

Peripheral neuropathy

34 (24.1)

0

1 (25.0)

0

3 (15.0)

0

20 (43.5)

0

0

0

9 (19.6)

0

0

0

1 (11.1)

0

Pneumonia

8 (5.7)

2 (1.4)

0

0

1 (5.0)

0

2 (4.3)

0

0

0

1 (2.2)

0

0

0

4 (44.4)

2 (22.2)

Hypertension

29 (20.6)

7 (5.0)

0

0

0

0

2 (4.3)

0

1 (10.0)

0

22 (47.8)

6 (13.0)

3 (50.0)

1 (16.7)

1 (11.1)

0

Anemia

78 (55.3)

17 (12.1)

1 (25.0)

0

8 (40.0)

4 (20.0)

29 (63.0)

5 (10.9)

5 (50.0)

1 (10.0)

25 (54.3)

3 (6.5)

4 (66.7)

1 (16.7)

5 (55.6)

3 (33.3)

Leukopenia

82 (58.2)

22 (15.6)

1 (25.0)

0

6 (30.0)

0

34 (74.0)

12 (26.1)

4 (40.0)

1 (10.0)

25 (54.3)

6 (13.0)

4 (66.7)

1 (16.7)

8 (88.9)

2 (22.2)

Neutropenia

51 (36.2)

21 (14.9)

1 (25.0)

0

3 (15.0)

1 (5.0)

23 (50.0)

11 (23.9)

3 (30.0)

2 (20.0)

15 (32.6)

4 (8.7)

4 (66.7)

2 (33.3)

2 (22.2)

1 (11.1)

Thrombocytopenia

48 (34.0)

14 (9.9)

1 (25.0)

0

6 (30.0)

3 (15.0)

12 (26.1)

3 (6.5)

5 (50.0)

4 (40.0)

16 (34.8)

2 (4.3)

3 (50.0)

1 (16.7)

5 (55.6)

1 (11.1)

Elevated ALT/AST

35 (24.8)

3 (2.1)

1 (25.0)

0

5 (25.0)

0

10 (21.7)

2 (4.3)

0

0

13 (28.3)

2 (4.3)

3 (50.0)

0

3 (33.3)

0

Proteinuria

21 (14.9)

4 (2.8)

0

0

0

0

1 (2.2)

0

0

0

16 (34.8)

4 (8.7)

5 (83.3)

1 (16.7)

0

0

Urinary occult blood

2 (1.4)

1 (0.7)

0

0

0

0

0

0

1 (10.0)

1 (10.0)

0

0

1 (16.7)

0

0

0

RCCEP

28 (19.9)

1 (0.7)

0

0

0

0

28 (60.9)

1 (2.2)

0

0

0

0

0

0

0

0

Hypothyroidism

6 (4.3)

1 (0.7)

0

0

0

0

4 (8.7)

1 (2.2)

0

0

2 (4.3)

0

0

0

0

0

Hyperglycemia

3 (2.1)

1 (0.7)

0

0

0

0

2 (4.3)

1 (2.2)

0

0

1 (2.2)

0

0

0

0

0

Hypokalemia

1 (0.7)

1 (0.7)

1 (25.0)

1 (25.0)

0

0

0

0

0

0

0

0

0

0

0

0

Stroke

1 (0.7)

1 (0.7)

0

0

0

0

0

0

0

0

1 (2.2)

1 (2.2)

0

0

0

0

Edema limbs

9 (6.4)

0

0

0

0

0

7 (15.2)

0

0

0

2 (4.3)

0

0

0

0

0

Skin ulceration

3 (2.1)

3 (2.1)

0

0

0

0

0

0

0

0

3 (6.5)

3 (6.5)

0

0

0

0

  1. ITT Intention-to-treat, ALT alanine aminotransferase, AST aspartate transaminase, PPE palmar-plantar erythrodysesthesia, RCCEP reactive cutaneous capillary endothelial proliferation.
  2. aEvents of any grade occurring in ≥ 10% of patients or grade 3–4 events occurring ≥ 1 patient are shown. No grade 5 events occurred.
  3. bBullous dermatitis.